Custom-engineered chimeric foot-and-mouth disease vaccine elicits protective immune responses in Pigs

Journal of General Virology

Volumn 92, Issue 4, 2011, Pages 849-859

  Blignaut, Belinda ^a,b   Visser, Nico ^c   Theron, Jacques ^b   Rieder, Elizabeth ^d   Maree, Francois F ^a  

^a ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c INTERVET INTERNATIONAL BV   (Netherlands)

^d PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; EMULSION; FEMALE; FOOT AND MOUTH DISEASE VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SWINE; VACCINATION; VIRION; VIRUS PARTICLE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EMULSIONS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; OILS; SWINE; SWINE DISEASES; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

CAVIA; FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE; SUIDAE;

EID: 79953251467     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.027151-0     Document Type: Article

References (46)

1. Amadori, M., Berneri, C. & Archetti, I. L. (1994). Immunogenicity of foot-and-mouth disease virus grown in BHK-21 suspension cells. Correlation with cell ploidy alterations and abnormal expression of the a5b1 integrin. Vaccine 12, 159-166.
2. Anderson, E. C., Masters, R. C. & Mowat, G. N. (1971). Immune response of pigs to inactivated foot-and-mouth disease vaccines. Response to emulsion vaccines. Res Vet Sci 12, 342-350.
3. Baranowski, E., Sevilla, N., Verdaguer, N., Ruiz-Jarabo, C. M., Beck, E. & Domingo, E. (1998). Multiple virulence determinants of foot-andmouth disease virus in cell culture. J Virol 72, 6362-6372.
4. Barnett, P. V. & Carabin, H. (2002). A review of emergency foot-andmouth disease (FMD) vaccines. Vaccine 20, 1505-1514.
5. Barnett, P. V., Pullen, L., Staple, R. F., Lee, L. J., Butcher, R., Parkinson, D. & Doel, T. R. (1996). A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of footand- mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. J Gen Virol 77, 1011-1018.
6. Barnett, P. V., Statham, R. J., Vosloo, W. & Haydon, D. T. (2003). Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach. Vaccine 21, 3240-3248.
7. Bastos, A. D. S., Haydon, D. T., Forsberg, R., Knowles, N. J., Anderson, E. C., Bengis, R. G., Nel, L. H. & Thomson, G. R. (2001). Genetic heterogeneity of SAT-1 type foot-and-mouth disease viruses in southern Africa. Arch Virol 146, 1537-1551.
8. Bastos, A. D. S., Haydon, D. T., Sangaré, O., Boshoff, C. I., Edrich, J. L. & Thomson, G. R. (2003). The implications of virus diversity within the SAT 2 serotype for control of foot-and-mouth disease in sub-Saharan Africa. J Gen Virol 84, 1595-1606.
9. Beard, C., Ward, G., Rieder, E., Chinsangaram, J., Grubman, M. J. & Mason, P. W. (1999). Development of DNA vaccines for foot-andmouth disease, evaluation of vaccines encoding replicating and nonreplicating nucleic acids in swine. J Biotechnol 73, 243-249.
10. Brehm, K. E., Kumar, N., Thulke, H. H. & Haas, B. (2008). High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 26, 1681-1687.
11. Burman, A., Clark, S., Abrescia, N. G. A., Fry, E. E., Stuart, D. I. & Jackson, T. (2006). Specificity of the VP1 GH loop of foot-andmouth disease virus for av integrins. J Virol 80, 9798-9810.
12. Cloete, M., Dungu, B., Van Staden, L. I., Ismail-Cassim, N. & Vosloo, W. (2008). Evaluation of different adjuvants for foot-and-mouth disease vaccine containing all the SAT serotypes. Onderstepoort J Vet Res 75, 17-31.
13. DiCara, D., Burman, A., Clark, S., Berryman, S., Howard, M. J., Hart, I. R., Marshall, J. F. & Jackson, T. (2008). Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin avb6: implications for infectiousness. J Virol 82, 1537-1546.
14. Doel, T. R. (1996). Natural and vaccine-induced immunity to foot and mouth disease: the prospects for improved vaccines. Rev Sci Tech 15, 883-911.
15. Doel, T. R. (2003). FMD vaccines. Virus Res 91, 81-99.
16. Doel, T. R. & Baccarini, P. J. (1981). Thermal stability of foot-andmouth disease virus. Arch Virol 70, 21-32.
17. Doel, T. R. & Collen, T. (1983). The detection and inhibition of proteolytic enzyme activity in concentrated preparations of inactivated foot-and-mouth disease virus. J Biol Stand 11, 35-46.
18. Doel, T. R. & Mowat, G. N. (1985). An international collaborative study on foot and mouth disease virus assay methods. 2. Quantification of 146S particles. J Biol Stand 13, 335-344.
19. Esterhuysen, J. J. (1994). The antigenic variation of foot-and-mouth disease viruses and its significance in the epidemiology of the disease in Southern Africa. MSc thesis, University of Pretoria, South Africa.
20. Esterhuysen, J. J., Thomson, G. R., Ashford, W. A., Lentz, D. W., Gainaru, M. D., Sayer, A. J., Meredith, C. D., Janse van Rensburg, D. & Pini, A. (1988). The suitability of a rolled BHK21 monolayer system for the production of vaccines against the SAT types of foot-andmouth disease virus. I. Adaptation of virus isolates to the system, immunogen yields achieved and assessment of subtype cross reactivity. Onderstepoort J Vet Res 55, 77-84.
21. European Pharmacopoeia (2006). Foot-and-mouth disease (ruminants) vaccine (inactivated) 04/2005:0063, 5th edn, version 5.5.
22. Fox, G., Parry, N. R., Barnett, P. V., McGinn, B., Rowlands, D. J. & Brown, F. (1989). The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycineaspartic acid). J Gen Virol 70, 625-637.
23. Fry, E. E., Lea, S. M., Jackson, T., Newman, J. W. I., Ellard, F. M., Blakemore, W. E., Abu-Ghazaleh, R., Samuel, A., King, A. M. Q. & Stuart, D. I. (1999). The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 18, 543-554.
24. Hunter, P. (1996). The performance of southern African territories serotypes of foot and mouth disease antigen in oil-adjuvanted vaccines. Rev Sci Tech 15, 913-922.
25. Jackson, T., Ellard, F. M., Ghazaleh, R. A., Brookes, S. M., Blakemore, W. E., Corteyn, A. H., Stuart, D. I., Newman, J. W. I. & King, A. M. Q. (1996). Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 70, 5282-5287.
26. Jackson, T., King, A. M. Q., Stuart, D. I. & Fry, E. (2003). Structure and receptor binding. Virus Res 91, 33-46.
27. Kärber, G. (1931). Beitrag zur kollektiven behandlung pharmakologischer Rreihenversuche. Naunyn Schmiedebergs Arch Pharmacol 162, 480-483 (in German).
28. King, A. M. Q. (2000). Picornaviridae. In Virus Taxonomy (Seventh Report of the International Committee for the Taxonomy of Viruses), pp. 657-673. Edited by M. H. V. Van Regenmortel. New York: Academic Press.
29. Knipe, T., Rieder, E., Baxt, B., Ward, G. & Mason, P. W. (1997).Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol 71, 2851-2856.
30. Reeve, R., Blignaut, B., Esterhuysen, J. J., Opperman, P., Matthews, L., Fry, E. E., de Beer, T. A. P., Theron, J., Rieder, E. & other authors (2010). Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus. PLoS Comput Biol 6, e1001027.
31. Maree, F. F., Blignaut, B., de Beer, T. A., Visser, N. & Rieder, E. A. (2010). Mapping of amino acid residues responsible for adhesion of cell culture-adapted foot-and-mouth disease SAT type viruses. Virus Res 153, 82-91.
32. Mason, P. W., Rieder, E. & Baxt, B. (1994). RGD sequence of footand- mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci U S A 91, 1932-1936.
33. McCullough, K. C., De Simone, F., Brocchi, E., Capucci, L., Crowther, J. R. & Kihm, U. (1992). Protective immune response against footand- mouth disease. J Virol 66, 1835-1840.
34. Office International des Epizooties (2009). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2009, Chapter 2.1.5, pp. 1-25. Paris, France: Office International des Epizooties.
35. Pay, T. W. F. (1983). Variation in foot and mouth disease: application to vaccination. Rev sci tech Off int Epiz 2, 701-723.
36. Rieder, E., Bunch, T., Brown, F. & Mason, P. W. (1993). Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol 67, 5139-5145.
37. Rieder, E., Baxt, B., Lubroth, J. & Mason, P. W. (1994). Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol 68, 7092-7098.
38. Rweyemamu, M. M. (1978). The selection of vaccine strains of foot and mouth disease virus. Br Vet J 134, 63-67.
39. Sa-Carvalho, D., Rieder, E., Baxt, B., Rodarte, R., Tanuri, A. & Mason, P. W. (1997). Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71, 5115-5123.
40. Sevilla, N., Verdaguer, N. & Domingo, E. (1996). Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus. Virology 225, 400-405.
41. Storey, P., Theron, J., Maree, F. F. & O'Neill, H. G. (2007). A second RGD motif in the 1D capsid protein of a SAT1 type foot-and-mouth disease virus field isolate is not essential for attachment to target cells. Virus Res 124, 184-192.
42. van Rensburg, H. G., Henry, T. M. & Mason, P. W. (2004). Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for footand- mouth disease virus. J Gen Virol 85, 61-68.
43. Vianna Filho, Y. L., Astudillo, V., Gomes, I., Fernández, G., Rozas, C. E. E., Ravison, J. A. & Alonso, A. (1993). Potency control of footand- mouth disease vaccine in cattle. Comparison of the 50% protective dose and the protection against generalization. Vaccine 11, 1424-1428.
44. Vosloo, W., Kirkbride, E., Bengis, R. G., Keet, D. F. & Thomson, G. R. (1995). Genome variation in the SAT types of foot-and-mouth disease viruses prevalent in buffalo (Syncerus caffer) in the Kruger National Park and other regions of southern Africa, 1986-93. Epidemiol Infect 114, 203-218.
45. Ward, M. P., Laffan, S. W. & Highfield, L. D. (2007). The potential role of wild and feral animals as reservoirs of foot-and-mouth disease. Prev Vet Med 80, 9-23.
46. Zibert, A., Maass, G., Strebel, K., Falk, M. M. & Beck, E. (1990). Infectious foot-and-mouth disease virus derived from a cloned fulllength cDNA. J Virol 64, 2467-2473.